SCHEDULE: Caligan Partners Discloses 8.5% Stake in Opus Genetics

Caligan Partners LP and David Johnson have reported beneficial ownership of 8.5% of Opus Genetics, Inc. common stock as of March 31, 2026.

Summary

• Caligan Partners LP, acting as an investment manager for various funds and accounts, along with David Johnson, the Managing Partner, have disclosed their beneficial ownership of Opus Genetics, Inc. common stock.
• As of March 31, 2026, the Reporting Persons collectively beneficially owned 6,075,028 shares of Opus Genetics' common stock.
• This ownership stake represents 8.5% of the total outstanding common stock.
• The filing is made under Schedule 13G, indicating the ownership is not for the purpose of changing or influencing control of the issuer.
• The total number of outstanding shares of common stock used for the percentage calculation was 71,402,472 as of March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but does not provide operational or financial updates that would directly impact the company's valuation or future performance.

Positives

• Caligan Partners LP and David Johnson have established a significant ownership position in Opus Genetics, Inc., holding 8.5% of the outstanding common stock.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, suggesting a passive investment approach rather than an attempt at control.

Future Outlook

This filing does not contain forward-looking statements or guidance from the company. It is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment managers accumulating significant stakes in public companies. This filing indicates Caligan Partners LP's interest in Opus Genetics, Inc., a biotechnology company, and their passive investment strategy.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor like Caligan Partners LP may be viewed positively, suggesting confidence in the company's future. However, the passive nature of the filing means no immediate strategic changes are implied.
• Management: The filing confirms an active institutional investor's interest, which may lead to increased scrutiny or engagement regarding corporate strategy and performance.
• Creditors: No direct impact is indicated, as the filing pertains to equity ownership and not debt.

Key Dates

Keywords

Opus Genetics, Caligan Partners LP, Schedule 13G, beneficial ownership, common stock, investment manager, David Johnson, SEC filing